Delving into the Latest Updates on AMT-151 with Synapse

Overview

Basic Info

Drug Type

Antibody drug conjugate (ADC)

Synonyms

Target-

Action-

Mechanism-

Therapeutic Areas

NeoplasmsDigestive System DisordersEndocrinology and Metabolic Disease+ [4]

Active Indication

Adenocarcinoma of LungAdvanced Malignant Solid NeoplasmEndometrial Carcinoma+ [13]

Inactive Indication-

Originator Organization

Multitude Therapeutics, Inc.

Active Organization

Multitude Therapeutics, Inc. (China)

Multitude, Inc.

Inactive Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

Structure/Sequence

Boost your research with our ADC technology data.

login

or

view full example data

Boost your research with our ADC technology data.

主要目的： 1）确定AMT-151的最大耐受剂量（MTD）和推荐II期剂量（RP2D）。 2）评估AMT-151的安全性和耐受性。次要目的： 1）初步评价AMT-151的抗肿瘤活性。 2）评价AMT-151的药代动力学（PK）特征。 3）评价AMT-151的免疫原性。探索性目的： 1）评价AMT-151的药效学（PD）特征。 2）评价叶酸途径血液标志物对FRα表达和AMT-151治疗反应的影响。

[Translation]

Primary objectives: 1) Determine the maximum tolerated dose (MTD) and recommended phase II dose (RP2D) of AMT-151. 2) Evaluate the safety and tolerability of AMT-151. Secondary objectives: 1) Preliminary evaluation of the anti-tumor activity of AMT-151. 2) Evaluate the pharmacokinetic (PK) characteristics of AMT-151. 3) Evaluate the immunogenicity of AMT-151. Exploratory objectives: 1) Evaluate the pharmacodynamic (PD) characteristics of AMT-151. 2) Evaluate the effects of folate pathway blood markers on FRα expression and AMT-151 treatment response.

Start Date-

Sponsor / Collaborator

Multitude Therapeutics, Inc. (China)

NCT05498597

/ RecruitingPhase 1

First-in-Human, Phase 1 Study of AMT-151, an Anti-Folate Receptor Alpha Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours

This first-in-human study will evaluate the Maximum Tolerated Dose (MTD) / the Recommended Phase 2 Dose (RP2D), safety, tolerability, anti-tumor activity, pharmacokinetics, pharmacodynamics and immunogenicity of AMT-151, a novel antibody-drug conjugate against folate receptor alpha, in patients with selected advanced solid tumors.

Start Date25 Jan 2023

Sponsor / Collaborator

Multitude, Inc.

[+1]

100 Clinical Results associated with AMT-151

Login to view more data

100 Translational Medicine associated with AMT-151

Login to view more data

100 Patents (Medical) associated with AMT-151

Login to view more data

100 Deals associated with AMT-151

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Endometrial Carcinoma	Phase 1	China	Multitude Therapeutics, Inc. (China)	25 Jan 2023
Endometrial Carcinoma	Phase 1	Australia	Multitude Therapeutics, Inc. (China)	25 Jan 2023
Endometrial Endometrioid Adenocarcinoma	Phase 1	Australia	Multitude, Inc.	25 Jan 2023
Endometrial Endometrioid Adenocarcinoma	Phase 1	China	Multitude, Inc.	25 Jan 2023
Fallopian Tube Carcinoma	Phase 1	Australia	Multitude Therapeutics, Inc. (China)	25 Jan 2023
Fallopian Tube Carcinoma	Phase 1	China	Multitude Therapeutics, Inc. (China)	25 Jan 2023
Ovarian Mucinous Adenocarcinoma	Phase 1	China	Multitude, Inc.	25 Jan 2023
Ovarian Mucinous Adenocarcinoma	Phase 1	Australia	Multitude, Inc.	25 Jan 2023
Primary peritoneal carcinoma	Phase 1	Australia	Multitude Therapeutics, Inc. (China)	25 Jan 2023
Primary peritoneal carcinoma	Phase 1	China	Multitude Therapeutics, Inc. (China)	25 Jan 2023

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data